<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

Pharmacy News and Stories

Advocacy

Students    Pharmacy    Advocacy

P4 Advocates for the Pharmacy Profession at the Colorado State Legislature

The best part about being a student at CU Pharmacy is the ample opportunities we are granted through school. We have access to renowned preceptors and diverse experiences for our Advanced Pharmacy Practice Experience (APPE) rotations. I was lucky enough to have my elective APPE rotation with Gina Moore, PharmD, and Emily Zadvorny, PharmD, legislative chair/past president and current Executive Director of Colorado Pharmacists Society (CPS), respectively. This rotation was certainly unconventional being that it was not clinical at all, but rather policy and advocacy focused.


Author cupharmacy | Publish Date April 25, 2022
Full Story

Research    Pharmacy    Advocacy

School of Pharmacy Joins Nationwide Medication/Vaccine Initiative

The University of Colorado Skaggs School of Pharmacy announced that it is joining the RAPID Alliance Medications 360 Study, with a goal of transforming how medications and vaccines are delivered in the US from 2022 – 2031. The RAPID Alliance is a multi-stakeholder research consortium founded in the University of Louisville Center for Health Organization Transformation (CHOT), a National Science Foundation-funded research center.


Author cupharmacy | Publish Date October 12, 2021
Full Story

School of Pharmacy In the News

Medscape

Medical Cannabis for Chronic Pain Tied to Arrhythmia Risk

news outletMedscape
Publish DateFebruary 13, 2024

Adults using medical cannabis for chronic pain, especially those with cancer or cardiometabolic disease, have a slightly elevated risk of developing arrhythmia, according to an editorial by Robert Page, PharmD

Full Story
KDVR

Colorado company developing potential prescription psilocybin product

news outletKDVR
Publish DateJanuary 17, 2024

Dr. David Kroll, PhD, says right now psilocybin is listed as a schedule one drug with no medical benefit and a high potential for abuse. “So, it is a risky proposition for these companies," he said, "but the clinical trials that have come out to date have been so promising that these companies have been able to acquire investors."

Full Story
The Denver Post

Littleton company developing psilocybin microdosing drug in hopes of FDA approval

news outletThe Denver Post
Publish DateJanuary 09, 2024

Though they hope to gain FDA approval soon, it may take some time. Dr. David Kroll, PhD, said the company will have additional hurdles to clear with the agency. 

Full Story
Neurology Today

Neurology Drugs Are Getting Better—and More Expensive—With More Prior Authorization Hassles

news outletNeurology Today
Publish DateJanuary 04, 2024

“The payers are trying to squeeze wherever they can,” said Dr. Kavita Nair, PhD, FAAN, a neurology professor and pharmacy outcomes researcher at the University of Colorado and vice chair of the American Academy of Neurology's Coding and Payment Policy Subcommittee.

Full Story